PP
FATE icon

PDT Partners’s Fate Therapeutics FATE Stock Holding History

PDT Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-138,814
Closed -$294K – 578
2023
Q3 		$294K Buy
+138,814
New +$460K 0.04% 480
2022
Q3 		– Sell
-20,683
Closed -$513K – 915
2022
Q2 		$513K Buy
+20,683
New +$571K 0.05% 593
2021
Q4 		– Sell
-19,482
Closed -$1.16M – 913
2021
Q3 		$1.16M Buy
+19,482
New +$1.53M 0.08% 317
2021
Q2 		– Sell
-2,667
Closed -$220K – 848
2021
Q1 		$220K Buy
+2,667
New +$256K 0.02% 688
2020
Q4 		– Sell
-8,749
Closed -$350K – 738
2020
Q3 		$350K Buy
+8,749
New +$305K 0.02% 527

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

PDT Partners's FATE Position: Q4 2023 in Review

PDT Partners sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 138,814 shares — an estimated $294K sold.

PDT Partners first reported a position in FATE in Q3 2020 and held it in 5 quarters. The position peaked at $1.16M in Q3 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • PDT Partners reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • PDT Partners sold 138,814 Fate Therapeutics shares in Q4 2023, an estimated $294K.
  • PDT Partners first reported a position in Fate Therapeutics in Q3 2020 and held it in 5 quarters.
  • PDT Partners's Fate Therapeutics position peaked at $1.16M in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on PDT Partners's 13F filing for Q4 2023, filed 14 Feb 2024.